Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
Fiche publication
Date publication
octobre 2016
Journal
The American journal of gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Cheddani H, Dauchet L, Fumery M, Charpentier C, Marie Bouvier A, Dupas JL, Pariente B, Peyrin-Biroulet L, Savoye G, Gower-Rousseau C
Lien Pubmed
Résumé
Cancer may be a complication of inflammatory bowel disease (IBD) or its treatment. In elderly onset IBD patients the risk of malignancy is of particular concern. We studied this risk in a population-based cohort of elderly onset IBD patients.
Mots clés
Adrenal Cortex Hormones, therapeutic use, Age of Onset, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, therapeutic use, Azathioprine, therapeutic use, Carcinoma, epidemiology, Colitis, Ulcerative, drug therapy, Colorectal Neoplasms, epidemiology, Crohn Disease, drug therapy, Female, Follow-Up Studies, France, epidemiology, Humans, Immunosuppressive Agents, therapeutic use, Incidence, Inflammatory Bowel Diseases, drug therapy, Intestinal Neoplasms, epidemiology, Lymphoproliferative Disorders, epidemiology, Male, Mesalamine, therapeutic use, Methotrexate, therapeutic use, Middle Aged, Myeloproliferative Disorders, epidemiology, Neoplasms, epidemiology, Proportional Hazards Models, Protective Factors, Registries, Retrospective Studies, Risk Factors, Time Factors, Tumor Necrosis Factor-alpha, antagonists & inhibitors
Référence
Am. J. Gastroenterol.. 2016 Oct;111(10):1428-1436